The Hamieds let professionals run Cipla — and then let them hand it on

Cipla is one of the oldest family stories in Indian business. Khwaja Abdul Hamied, a chemist trained in Germany, founded it in 1935 as Chemical, Industrial & Pharmaceutical Laboratories. His son Yusuf, a Cambridge PhD who joined as a scientist, took over at their father's death in 1972. Yusuf turned Cipla into the world's conscience on drug pricing: his three-drug AIDS cocktail sold for roughly $304 a year against the $12,000 charged by Western drugmakers, and at one point as much as 40 per cent of AIDS patients in poor countries took Cipla medicines.

In 2016 the family broke with nine decades of Hamied management and named Umang Vohra — a former Dr Reddy's executive — managing director and global chief executive. Over his tenure from 2016 to 2025, consolidated net sales grew from Rs 11,345 crore in FY15 to Rs 27,548 crore in FY25, a 9.2 per cent compound rate, while EBITDA margins moved from the mid-teens to sustained mid-20s and market value climbed from about Rs 45,700 crore in 2016 to Rs 1.27 lakh crore by October 2025. The company built a cash pile of roughly Rs 10,000 crore along the way.

The proof of the design came at the exit. In late 2025 Cipla announced that Vohra would step down and that Achin Gupta — who had joined the company in 2021 to run its One India business and become global chief operating officer in February 2025 — would take over as managing director and global CEO from 1 April 2026. 'The task I had set out to do through my two terms is achieved,' Vohra said. 'Cipla is now in good hands.' A professional was handing the family firm to another professional.

Sales rose from Rs 11,345 crore in FY15 to Rs 27,548 crore in FY25 and market value climbed about 2.8 times to Rs 1.27 lakh crore under professional management

A 90-year-old generics giant competing across the US, South Africa and India had outgrown founder-run management, and its complexity demanded operators rather than owners.

The family had already proved it could separate legacy from job titles: the Hamied name stood for the company's mission, not for the executive chair.

Vohra's decade created its own succession pipeline — Gupta rose through the India business to global COO, so the board promoted a tested insider rather than gambling on a stranger.

The balance-sheet strength built under professional management gave the board the freedom to change CEOs from a position of strength rather than in a crisis.

A founding family can keep the company it built without supplying every chief executive: hand the job to proven operators and let them build the bench that succeeds them.

Gupta took charge on 1 April 2026 inheriting roughly Rs 10,000 crore of cash and a respiratory-led portfolio; analysts warned that 'no low-hanging fruits' remained in generics. The family's freedom to choose its own path was tested too: in 2023 Blackstone prepared a bid for the Hamied family's entire 33.47 per cent promoter stake — potentially India's largest private-equity buyout — but no sale followed. Samina Hamied, Yusuf's niece, held the executive vice-chairperson's role through the approach, keeping the family at the boardroom table.